Schrodinger's Drug Discovery Platform: Where Did All the Pharma Partnerships Go?

Schrödinger, Inc. (NASDAQ: SDGR) reports second quarter 2026 earnings after market close on August 5, 2026—just one day away. The computational drug discovery platform provider faces a critical test after last quarter's disappointing miss raised questions about the sustainability of its software growth trajectory. With analysts expecting continued losses but watching for signs of stabilization in its core software business, this report will determine whether SDGR can regain investor confidence or faces further pressure.

Part 1: Earnings Preview

Schrödinger develops physics-based computational platforms for drug discovery and materials design, serving pharmaceutical and biotechnology companies through both software licensing and collaborative drug discovery partnerships. The company's business model combines recurring software revenue with milestone-based drug discovery income, making quarterly performance sensitive to both subscription trends and partnership progress.

Analysts expect SDGR to report a loss of $0.60 per share for Q2 2026, with estimates ranging from $0.43 to $0.82 per share among three analysts. The company most recently reported a loss of $0.81 per share in Q1 2026, significantly worse than the $0.56 consensus estimate. Compared to the same quarter last year when SDGR lost $0.59 per share, the current estimate implies a 1.69% deterioration year-over-year—a modest widening of losses that reflects ongoing investment in the platform.

Three key themes define this earnings story:

Software Revenue Mix and Hosted Adoption: Management's multi-year target of reaching approximately 75% hosted software mix represents a critical strategic shift. Q1 showed hosted software at 34% of total software revenue ($12.1M of $35.6M), with a trailing four-quarter average of 27%. Investors will scrutinize whether Q2 shows continued progress toward this goal, as hosted solutions typically drive higher margins and stickier customer relationships. The company's Q2 ACV guidance of $19–$23M (excluding contribution ACV) provides a benchmark, though Q1's $28.4M beat suggests potential upside.

Drug Discovery Revenue Volatility: Q1's drug discovery revenue of $22.9M more than doubled from $10.2M in the prior-year quarter, demonstrating the lumpy nature of milestone-based income. With full-year guidance of $55–$65M, Q2 performance will indicate whether the strong Q1 represents sustainable momentum or timing-related concentration. Strategic partnerships remain essential for validating Schrödinger's platform capabilities and providing long-term revenue visibility beyond software subscriptions.

Operating Expense Discipline: Management's commitment to keeping 2026 operating expenses below 2025 levels takes on heightened importance after Q1's $60M net loss. With clinical R&D expected at $10–$15M for the full year as clinical activities wind down, investors will watch whether the company can maintain its innovation pipeline while improving the path to profitability. Q1 operating expenses of $78M (down 4% from $82M prior year) set a baseline for evaluating cost management progress.

Analyst commentary ahead of the release reflects cautious optimism tempered by execution concerns. The maintained full-year ACV guidance of $218–$228M (10–15% growth) provides a framework, but the Q1 miss on earnings despite revenue performance suggests margin pressure remains a key risk factor.

Part 2: Historical Earnings Performance

Schrödinger has delivered a mixed earnings track record over the past four quarters, with two significant beats followed by two misses that bookended the period. The pattern reveals improving operational execution in the middle quarters that deteriorated sharply in the most recent report.

The company posted its strongest performance in Q4 2025, delivering earnings of $0.44 per share against a $0.13 loss estimate—a stunning 438.46% beat that likely reflected favorable revenue recognition timing or one-time items. This followed a solid Q3 2025 result where SDGR lost $0.45 per share versus the $0.75 expected loss, a 40.00% beat. Q2 2025 also exceeded expectations with a $0.59 loss compared to the $0.83 consensus, representing a 28.92% beat.

However, the most recent Q1 2026 report broke this positive streak decisively. SDGR reported a loss of $0.81 per share against expectations for a $0.56 loss, missing by 44.64%—the worst surprise in this four-quarter window. This sharp reversal suggests the Q4 profitability may have been unsustainable and raises questions about whether the company's cost structure can support its current growth investments. The magnitude of the Q1 miss makes the upcoming Q2 report critical for determining whether execution challenges are temporary or signal deeper issues with the business model transition.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Schrödinger reports after market close, meaning Day 0 captures anticipatory trading before results are released, while Day +1 reflects the market's first full session to digest the actual numbers.

Historical price action shows moderate volatility around earnings, with Day 0 moves averaging 3.28% and Day +1 moves averaging 2.52%. The Day +1 intraday range of 10.85% indicates substantial trading activity as investors reassess positions after results.

The most dramatic reaction came in November 2024, when the stock surged 13.87% on Day 0 in anticipation, though it gave back some gains the following session. More recently, the February 2026 report triggered a 4.42% Day 0 gain followed by an 8.14% Day +1 advance—both above-average moves reflecting positive sentiment. Conversely, the May 2026 report (Q1 2026 results) produced minimal Day 0 movement at just 0.23% decline, with modest Day +1 follow-through of 0.85% gain despite the significant earnings miss.

The average absolute Day 0 move of 3.28% suggests investors typically position cautiously ahead of results, while the 10.85% average Day +1 range indicates the stock can swing significantly once actual numbers are released. Recent quarters show Day +1 ranges consistently exceeding 11%, pointing to heightened uncertainty about the company's trajectory.

Part 2.2: Options Market Expected Move

The options market is pricing a 12.33% expected move through the August 21 monthly expiration—notably higher than the 10.85% average Day +1 range from historical earnings. This elevated implied volatility of 80.47% suggests options traders are anticipating above-average price movement, possibly reflecting uncertainty about whether SDGR can stabilize performance after last quarter's disappointing miss.

Part 3: What Analysts Are Saying

Analysts maintain a bullish stance on SDGR despite recent execution challenges, with a consensus rating of 4.25 (Buy) based on eight analysts. The breakdown shows 5 Strong Buy ratings and 3 Hold ratings, with no sell recommendations. However, sentiment has deteriorated slightly from one month ago when the average rating stood at 4.33 with six Strong Buys.

The average price target of $20.57 implies 31.4% upside from the current price of $15.65, with estimates ranging from a low of $13.00 to a high of $30.00. This wide target range reflects divergent views on the company's ability to execute its strategic transition to hosted software and scale its drug discovery partnerships. The high-end target of $30.00 suggests some analysts see substantial value in SDGR's computational platform if execution improves, while the $13.00 low target indicates concerns about near-term profitability challenges.

The recent downgrade from six to five Strong Buy ratings signals growing caution among the analyst community following the Q1 miss. While the overall Buy consensus remains intact, the shift suggests analysts are adopting a more wait-and-see posture heading into Q2 results, wanting evidence that management can deliver on its full-year guidance before reaffirming more aggressive bullish calls.

Part 4: Technical Picture

SDGR enters earnings with strengthening technical momentum, as the Barchart Technical Opinion has surged to an 80% Buy signal from just 32% one week ago and 40% one month ago. This sharp improvement reflects growing positive price action heading into the report, though the "Soft" strength designation suggests the trend lacks deep conviction.

The stock is trading at $15.65, positioned above all major moving averages: the 5-day ($15.31), 10-day ($15.22), 20-day ($15.57), 50-day ($15.37), 100-day ($13.73), and 200-day ($15.20). This universal support across timeframes indicates technical buyers have stepped in across multiple horizons, with the 100-day average showing the strongest relative support at 14% below current levels.

Timeframe Analysis:

• Short-term (100% Buy): Maximum bullish signal indicates strong near-term momentum heading into earnings, suggesting technical traders are positioned for positive results
• Medium-term (100% Buy): Equally strong intermediate-term signal reflects sustained buying pressure over recent weeks, providing a supportive backdrop
• Long-term (50% Buy): Moderate bullish reading suggests the longer-term trend remains constructive but less emphatic, indicating some caution about durability

Trend Characteristics: The strengthening but soft trend suggests improving technical conditions that lack the deep conviction typically seen at major turning points, leaving the setup vulnerable to disappointment if earnings underwhelm.

The technical setup is cautiously supportive heading into earnings, with the stock holding above all key moving averages and generating strong short- and medium-term buy signals. However, the 12.33% options-implied move exceeds typical historical volatility, suggesting the market is pricing in potential for a larger-than-normal reaction. The 20-day moving average at $15.57 represents immediate support just 0.5% below current levels, while the 50-day at $15.37 provides a secondary floor. A positive earnings surprise could target the $17.58 upper end of the options-implied range, while disappointment might test support near the $13.72 lower bound—levels that would challenge but not necessarily break the broader uptrend structure.